for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lonza Group AG

LONN.S

Latest Trade

607.00CHF

Change

-5.40(-0.88%)

Volume

234,676

Today's Range

600.20

 - 

615.80

52 Week Range

516.20

 - 

785.40

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
612.40
Open
612.40
Volume
234,676
3M AVG Volume
3.09
Today's High
615.80
Today's Low
600.20
52 Week High
785.40
52 Week Low
516.20
Shares Out (MIL)
74.28
Market Cap (MIL)
45,604.66
Forward P/E
45.83
Dividend (Yield %)
0.49

Next Event

Full Year 2021 Lonza Group AG Earnings Release

Latest Developments

More

Lonza Group Launches bYlok Technology

Lonza And Agilent Announce Strategic Collaboration To Integrate New Analytical Technologies

Lonza Says To Acquire Exosomics Service Unit In Italy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Lonza Group AG

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.

Industry

Biotechnology & Drugs

Contact Info

Muenchensteinerstrasse 38

4002

Switzerland

+41.61.3168111

https://www.lonza.com/

Executive Leadership

Albert M. Baehny

Independent Chairman of the Board

Pierre-Alain Ruffieux

Chief Executive Officer, Member of the Executive Committee

Rodolfo Savitzky

Chief Financial Officer, Member of the Executive Committee

Caroline Barth

Chief Human Resource Officer, Member of the Executive Committee

Stefan Stoffel

Chief Operating Officer of Lonza Pharma Biotech and Nutrition, Member of the Executive Committee

Key Stats

2.14 mean rating - 22 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2018

5.5K

2019

5.9K

2020

4.5K

2021(E)

5.2K
EPS (CHF)

2018

11.980

2019

13.590

2020

12.190

2021(E)

13.422
Price To Earnings (TTM)
88.95
Price To Sales (TTM)
11.47
Price To Book (MRQ)
6.26
Price To Cash Flow (TTM)
45.93
Total Debt To Equity (MRQ)
50.19
LT Debt To Equity (MRQ)
38.38
Return on Investment (TTM)
4.32
Return on Equity (TTM)
3.55

Latest News

Latest News

Lonza updates mid-term guidance, sees no extraordinary payouts

Lonza Group gave 2024 guidance on Tuesday for "low teens" sales growth at constant exchange rates, a core EBITDA margin of around 33-35%, and double-digit return on invested capital.

Lonza extends antibody drug conjugate supply deal with biotech client

Lonza Group has extended a collaboration with a major biopharmaceutical industry client for the supply of an antibody drug conjugate (ADC) against hard-to-treat cancers, the Swiss contract drugmaker said in a statement on Friday.

Lonza restates FY 2020 core EBITDA

Lonza Group on Tuesday restated its 2020 results to reflect the discontinuation of its specialty ingredients business, as well as a rejig of its business structure and performance measurement policy.

Swiss government stocks up Lonza workforce to help make Moderna vaccine

The Swiss government said on Wednesday it recruited 75 people including federal and university employees to temporarily staff facilities at Lonza, which struggled to find personnel to make ingredients for Moderna's COVID-19 vaccine.

OFFICIAL CORRECTION-BRIEF-Lonza CFO Comments On Drug Substance Production For Moderna COVID-19 Vaccine - J.P.Morgan Conf

* LONZA GROUP CFO CONFIRMS THAT LONZA FORECASTS THE PRODUCTION OF DRUG SUBSTANCE EQUIVALENT TO 400 MILLION DOSES OF THE MODERNA COVID-19 VACCINE PER YEAR ONCE FULLY OPERATIONAL, AND NOT OVER THE FIRST QUARTER OF 2021 Further company coverage:

Lonza gets Swiss OK to start Moderna vaccine production -paper

Swiss regulators have allowed contract manufacturer Lonza Group to start producing Moderna's COVID-19 vaccine at a plant in Switzerland, the SonntagsZeitung newspaper reported.

Lonza to make COVID-19 antibody combination for AstraZeneca

Lonza Group has agreed with AstraZeneca to make AZD7442, an experimental combination of two antibodies that may be used to prevent and treat COVID-19, the Swiss contract manufacturer said on Friday.

Lonza adds microbial plant for Servier partnership

Swiss contract manufacturer Lonza Group is adding a mid-scale microbial facility to supply France's Laboratoires Servier with active pharmaceutical ingredient for acute lymphoblastic leukaemia therapies, Lonza said on Tuesday.

Lonza licenses technology to China's Junshi for experimental COVID-19 drug

Lonza Group said on Monday that China's Junshi Biosciences has licensed the Swiss contract drug manufacturer's technology to help produce a neutralizing antibody against COVID-19.

Exclusive: Lonza expects EPA approval 'very soon' to make COVID-killing claims for surface disinfectants

Lonza Group AG is in the “last step” of discussions with U.S. regulators for approval to claim that its formulation is effective in killing the novel Coronavirus on surfaces, an executive at the pharmaceutical and chemical giant told Reuters.

BRIEF-Lonza Establishes New Center For Particle Engineering

* LONZA ESTABLISHES A NEW CENTER OF EXCELLENCE TO LEVERAGE ITS CORE PARTICLE ENGINEERING EXPERTISE UTILIZING BOTH PARTICLE SIZE REDUCTION AND SPRAY DRYING TECHNOLOGIES

Lonza COO Abend leaving for German CEO job

Lonza Group Chief Operating Officer Sven Abend, also head of its Lonza Specialty Ingredients (LSI) business, is resigning to become chief executive of an unnamed German company, the Swiss contract manufacturer said on Tuesday.

BRIEF-Lonza Partners With Cellink To Offer 3D Bioprinting Solution

* HAS COLLABORATED WITH CELLINK TO OFFER A COMPREHENSIVE 3-DIMENSIONAL (3D) BIOPRINTING SOLUTION

Lonza picks Roche executive as CEO, ending year of turmoil at the top

Lonza Group on Friday named a veteran Roche manager to become its new chief executive, as the Swiss contract drug manufacturer seeks to end a year of turmoil at the top and accelerates work to produce a possible COVID-19 vaccine.

Lonza taps Roche executive Ruffieux as new CEO

Swiss contract drug manufacturer Lonza Group on Friday named Roche executive Pierre-Alain Ruffieux as its new chief executive effective from Nov. 1.

BRIEF-Lonza Group Requests Trading Halt

* LONZA GROUP LTD (REQUEST FOR TRADING HALT) Source text for Eikon: Further company coverage:

Moderna, Switzerland's Lonza strike deal on potential COVID-19 vaccine

Moderna Inc and Swiss contract drugmaker Lonza Group AG said on Friday they would accelerate the manufacturing of the U.S. drug developer's potential coronavirus vaccine.

Lonza Group to host AGM on April 28, dividend unchanged

Lonza on Friday said it would go ahead with its annual general meeting on April 28 without shareholders present, leaving its dividend proposal of 2.75 Swiss francs ($2.81) per share unchanged. ($1 = 0.9800 Swiss francs) (Reporting by Brenna Hughes Neghaiwi Editing by Michelle...

BRIEF-Lonza Chairman Says Says No Rush To Make Decision On Specialty Chemicals Business

* LONZA CHAIRMAN SAYS LONG-TERM STRATEGIC FOCUS IS ON BIOTECH, DRUG AND NUTRITION BUSINESS, OPTIONS FOR SPECIALTY CHEMICALS INCLUDE SALE, SPINOFF, IPO OR KEEP IN PORTFOLIO

BRIEF-Lonza Announces Price Increases For Some Ammonium Products

* LONZA ANNOUNCES PRICE INCREASES FOR SELECTED PRODUCTS IN ITS QUATS, AMINES AND AMINE OXIDES PORTFOLIOS GLOBALLY

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up